Fig. 7

Immunotherapy response and drug sensitivity analysis. A Differences of TIDE-related scores between C1 and C2. B Differences of TIDE-related scores among GC1-3. C Correlations of the risk score with TIDE-related scores. D Rate of predicted clinical response to ICB immunotherapy in different clusters and risk levels. E Differences in IC50 values of cisplatin, cyclophosphamide, gemcitabine and sorafenib between C1 and C2. F Differences in IC50 values of cisplatin, cyclophosphamide, gemcitabine and sorafenib among GC1-3. G Correlations of the risk score with IC50 values of cisplatin, cyclophosphamide, gemcitabine and sorafenib. *P < 0.05, **P < 0.01, ****P < 0.0001